Results 121 to 130 of about 4,164 (194)

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis [PDF]

, 2017
Brandi, Maria Luisa, Fan, M, Grauer, A., Karaplis, Ac, Lorentzon, M, Maddox, J, Meisner, Pd, Petersen, J, Saag, Kg, Thomas, T   +9 more
core   +1 more source

Romosozumab for the treatment of thalassemia-associated osteoporosis in two female patients. [PDF]

JBMR Plus
Yavropoulou MP, Koloutsou ME, Delaporta P, Makras P, Anastasilakis AD, Kassi E, Kattamis A, Xekouki P.   +7 more
europepmc   +1 more source

Increase in serum DKK1 levels attenuates the anabolic response to romosozumab in postmenopausal osteoporosis. [PDF]

J Bone Miner Res
Adami G, Montanari F, Fassio A, Pollastri F, Piccinelli A, Benini C, Pasetto E, Tugnolli M, Gatti D, Rossini M, Viapiana O.   +10 more
europepmc   +1 more source

3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial. [PDF]

Lancet Diabetes Endocrinol
Leder BZ, Ramchand SK, Jordan M, Ryan S, Patnaik A, Lee H, Tsai JN.   +6 more
europepmc   +1 more source

Romosozumab versus teriparatide [PDF]

Nature Reviews Rheumatology, 2017
openaire   +1 more source

Upper arm administration is associated with higher injection site pain with romosozumab: a randomized controlled trial and a self-controlled study. [PDF]

JBMR Plus
Tani S, Asada T, Hasegawa H, Passias P, Tsuchiya K, Ishikawa M, Richardson W, Kudo Y, Alman B, Ishikawa K.   +9 more
europepmc   +1 more source

Romosozumab Enhances Implant Stability in Glucocorticoid-Induced Osteoporotic Bone: A Rabbit Model Study. [PDF]

Neurospine
Kwon JW, Moon SH, Suk KS, Park SY, Kim HS, Park SR, Kim N, Lee BH.   +7 more
europepmc   +1 more source

Romosozumab after rebound vertebral fractures induced by denosumab discontinuation: a case series. [PDF]

JBMR Plus
Sarli M, Farias V, Abdala R, Armanelli E, Bocci C, Jerkovich F, Zanchetta MB.   +6 more
europepmc   +1 more source

Treatment patterns of romosozumab in postmenopausal women with severe osteoporosis in Denmark: findings from the ROmosozumab in Scandinavia real-world Evidence Study (ROSES). [PDF]

Osteoporos Int
Langdahl BL, Lorentzon M, Borgen TT, Bajtner E, Kaarill T, Alstad C, Rieem Dun A, Konradsen MS, Liseth Hansen J, Ström O, Tsitlakidis E, Moayyeri A.   +11 more
europepmc   +1 more source

Assessment of the efficacy and safety of anti-sclerostin antibody therapy for osteoporosis in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Front Endocrinol (Lausanne)
Chen L, Wang Q, Gu M.
europepmc   +1 more source